{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T04:00:55Z","timestamp":1774584055122,"version":"3.50.1"},"update-to":[{"DOI":"10.1002\/14651858.cd004683.pub3","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2016,5,31]],"date-time":"2016-05-31T00:00:00Z","timestamp":1464652800000}}],"reference-count":259,"publisher":"Wiley","issue":"5","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd004683.pub4","type":"journal-article","created":{"date-parts":[[2016,5,31]],"date-time":"2016-05-31T13:27:51Z","timestamp":1464701271000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Interventions for lowering plasma homocysteine levels in dialysis patients"],"prefix":"10.1002","volume":"2016","author":[{"given":"Sagar U","family":"Nigwekar","sequence":"first","affiliation":[{"name":"Harvard Medical School; Division of Nephrology, Massachusetts General Hospital, Scholars in Clinical Sciences Program; Boston MA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amy","family":"Kang","sequence":"additional","affiliation":[{"name":"The University of Sydney; Sydney Medical School; Sydney NSW Australia"},{"name":"The George Institute for Global Health, The University of Sydney; Renal and Metabolic Division; Camperdown NSW Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sophia","family":"Zoungas","sequence":"additional","affiliation":[{"name":"Monash University; Diabetes and Vascular Research Program, Monash Centre for Health Research and Implementation, School of Public Health and Preventive Medicine; Clayton VIC Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan","family":"Cass","sequence":"additional","affiliation":[{"name":"The George Institute for Global Health, The University of Sydney; Renal and Metabolic Division; Camperdown NSW Australia"},{"name":"Menzies School of Health Research; PO Box 41096 Casuarina NT Australia 0811"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin P","family":"Gallagher","sequence":"additional","affiliation":[{"name":"The George Institute for Global Health, The University of Sydney; Renal and Metabolic Division; Camperdown NSW Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satyarth","family":"Kulshrestha","sequence":"additional","affiliation":[{"name":"University of Iowa Carver College of Medicine; Department of Nephrology; 200 Hawkins Drive-T307GH Iowa City IA USA 52242"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sankar D","family":"Navaneethan","sequence":"additional","affiliation":[{"name":"Baylor College of Medicine; 1 Baylor Plaza Houston Texas USA 77030"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vlado","family":"Perkovic","sequence":"additional","affiliation":[{"name":"The George Institute for Global Health, The University of Sydney; Renal and Metabolic Division; Camperdown NSW Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni FM","family":"Strippoli","sequence":"additional","affiliation":[{"name":"The Children's Hospital at Westmead; Cochrane Kidney and Transplant, Centre for Kidney Research; Westmead NSW Australia 2145"},{"name":"University of Bari; Department of Emergency and Organ Transplantation; Bari Italy"},{"name":"Diaverum; Medical Scientific Office; Lund Sweden"},{"name":"Diaverum Academy; Bari Italy"},{"name":"The University of Sydney; Sydney School of Public Health; Sydney Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meg J","family":"Jardine","sequence":"additional","affiliation":[{"name":"The George Institute for Global Health, The University of Sydney; Renal and Metabolic Division; Camperdown NSW Australia"},{"name":"Concord Repatriation General Hospital; Department of Renal Medicine; Hospital Road Concord NSW Australia 2139"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2016,5,31]]},"reference":[{"issue":"Suppl 3","key":"10.1002\/14651858.CD004683.pub4-BIB0001|cit1","first-page":"A17","article-title":"The atherosclerosis and folic acid supplementation trial in CRF (ASFAST): rationale, design and baseline results [abstract no: 65]","volume":"7","author":"McGrath","year":"2002","journal-title":"Nephrology"},{"issue":"Program & Abstr","key":"10.1002\/14651858.CD004683.pub4-BIB0002|cit2","first-page":"228A","article-title":"The atherosclerosis and folic acid supplementation trial in CRF (ASFAST): rationale, design and baseline results [abstract]","volume":"12","author":"McGrath","year":"2001","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Abstracts","key":"10.1002\/14651858.CD004683.pub4-BIB0003|cit3","first-page":"92A","article-title":"The effect of lowering homocysteine on haemodialysis vascular access outcomes: the ASFAST randomised placebo controlled trial [abstract no: SU-FC110]","volume":"18","author":"Polkinghorne","year":"2007","journal-title":"Journal of the American Society of Nephrology"},{"issue":"3","key":"10.1002\/14651858.CD004683.pub4-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1111\/j.1440-1797.2004.00242.x","article-title":"Atherosclerosis and folic acid supplementation trial in chronic renal failure: baseline results","volume":"9","author":"Zoungas","year":"2004","journal-title":"Nephrology"},{"issue":"4","key":"10.1002\/14651858.CD004683.pub4-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1053\/j.ajkd.2007.07.012","article-title":"Association of carotid intima-medial thickness and indices of arterial stiffness with cardiovascular disease outcomes in CKD","volume":"50","author":"Zoungas","year":"2007","journal-title":"American Journal of Kidney Diseases"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD004683.pub4-BIB0006|cit6","first-page":"A133","article-title":"Chronic kidney disease, cardiovascular events and the effect of diabetes: post hoc analyses from ASFAST [abstract no: 128]","volume":"13","author":"Zoungas","year":"2008","journal-title":"Nephrology"},{"issue":"12","key":"10.1002\/14651858.CD004683.pub4-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1111\/j.1445-5994.2010.02226.x","article-title":"Advanced chronic kidney disease, cardiovascular events and the effect of diabetes: data from the Atherosclerosis and Folic Acid Supplementation Trial","volume":"41","author":"Zoungas","year":"2011","journal-title":"Internal Medicine Journal"},{"issue":"6","key":"10.1002\/14651858.CD004683.pub4-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1016\/j.jacc.2005.10.064","article-title":"Cardiovascular morbidity and mortality in the Atherosclerosis and Folic Acid Supplementation Trial (ASFAST) in chronic renal failure: a multicenter, randomized, controlled trial","volume":"47","author":"Zoungas","year":"2006","journal-title":"Journal of the American College of Cardiology"},{"key":"10.1002\/14651858.CD004683.pub4-BIB0009|cit9","unstructured":"Heinz J Dierkes J Domrose U Neumann KH Luley C Influence of a supplementation with vitamins on morbidity and mortality of ESRD patients: a multi-center randomly designed double blinded intervention trial; Prismavit - prospective intervention study from Magdeburg with vitamins [abstract] XIV Lipid Meeting; 2003 Dec 5-7; Leipzig, Germany 2003 89"},{"issue":"3","key":"10.1002\/14651858.CD004683.pub4-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"363","DOI":"10.5414\/CNP71363","article-title":"Influence of a supplementation with vitamins on cardiovascular morbidity and mortality in patients with end-stage renal disease: design and baseline data of a randomized clinical trial","volume":"71","author":"Heinz","year":"2009","journal-title":"Clinical Nephrology"},{"issue":"12","key":"10.1002\/14651858.CD004683.pub4-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1161\/CIRCULATIONAHA.109.904672","article-title":"B vitamins and the risk of total mortality and cardiovascular disease in end-stage renal disease: results of a randomized controlled trial","volume":"121","author":"Heinz","year":"2010","journal-title":"Circulation"},{"issue":"3","key":"10.1002\/14651858.CD004683.pub4-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1053\/j.ajkd.2009.05.013","article-title":"Homocysteine lowering and cognition in CKD: the Veterans Affairs homocysteine study","volume":"54","author":"Brady","year":"2009","journal-title":"American Journal of Kidney Diseases"},{"issue":"Nov","key":"10.1002\/14651858.CD004683.pub4-BIB0013|cit13","first-page":"832A","article-title":"High plasma homocysteine (Hcy) and cardiovascular (CV) disease in end stage (ESRD) and advanced chronic (ACKD) kidney disease. The VA Coop. study program homocysteine study (HOST) progress report [abstract no: PUB272]","volume":"14","author":"Jamison","year":"2003","journal-title":"Journal of the American Society of Nephrology"},{"issue":"5","key":"10.1002\/14651858.CD004683.pub4-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1191\/1740774504cn038oa","article-title":"Design and statistical issues in the homocysteinemia in kidney and end stage renal disease (HOST) study","volume":"1","author":"Jamison","year":"2004","journal-title":"Clinical Trials"},{"issue":"Oct","key":"10.1002\/14651858.CD004683.pub4-BIB0015|cit15","first-page":"132A","article-title":"Cardiovascular disease in patients with advanced chronic kidney disease (ACKD) and hyperhomocysteinemia. The VA Coop. Studies Program Homocysteine Study (HOST) [abstract no: F-PO300]","volume":"15","author":"Jamison","year":"2004","journal-title":"Journal of the American Society of Nephrology"},{"key":"10.1002\/14651858.CD004683.pub4-BIB0016|cit16","unstructured":"Jamison RL Hartigan P Kaufman JS Goldfarb DS Warren SR Guarino P Homocysteine lowering effect on mortality and vascular disease in advanced chronic kidney disease and end stage renal disease [abstract no: M-FC-041] 4th World Congress of Nephrology.19th International Congress of the International Society of Nephrology (ISN); 2007 Apr 21-25; Rio de Janeiro, Brazil 2007 211"},{"issue":"10","key":"10.1002\/14651858.CD004683.pub4-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1001\/jama.298.10.1163","article-title":"Effect of homocysteine lowering on mortality and vascular disease in advanced chronic kidney disease and end-stage renal disease: a randomized controlled trial.[Erratum appears in JAMA. 2008 Jul 9;300(2):170]","volume":"298","author":"Jamison","year":"2007","journal-title":"JAMA"},{"issue":"5","key":"10.1002\/14651858.CD004683.pub4-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1053\/j.ajkd.2008.12.023","article-title":"Effect of the MTHFR C677T and A1298C polymorphisms on survival in patients with advanced CKD and ESRD: a prospective study","volume":"53","author":"Jamison","year":"2009","journal-title":"American Journal of Kidney Diseases"},{"issue":"4","key":"10.1002\/14651858.CD004683.pub4-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"640","DOI":"10.2215\/CJN.07020711","article-title":"Racial differences in markers of mineral metabolism in advanced chronic kidney disease","volume":"7","author":"Jovanovich","year":"2012","journal-title":"Clinical Journal of the American Society of Nephrology: CJASN"},{"issue":"4","key":"10.1002\/14651858.CD004683.pub4-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1053\/j.ajkd.2012.04.014","article-title":"Associations of plasma 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D concentrations with death and progression to maintenance dialysis in patients with advanced kidney disease","volume":"60","author":"Kendrick","year":"2012","journal-title":"American Journal of Kidney Diseases"},{"key":"10.1002\/14651858.CD004683.pub4-BIB0021|cit21","first-page":"542A","article-title":"Fibroblast growth factor-23 and progression to dialysis in patients with advanced kidney disease [abstract no: F-PO1879]","volume":"20","author":"Kendrick","year":"2009","journal-title":"Journal of the American Society of Nephrology"},{"key":"10.1002\/14651858.CD004683.pub4-BIB0022|cit22","first-page":"540A","article-title":"Fibroblast growth factor-23 and the risk of death and cardiovascular events among patients with chronic kidney disease [abstract no: F-PO1873]","volume":"20","author":"Kendrick","year":"2009","journal-title":"Journal of the American Society of Nephrology"},{"key":"10.1002\/14651858.CD004683.pub4-BIB0023|cit23","first-page":"547A","article-title":"Higher intact parathyroid hormone levels are not associated with all-cause mortality or cardiovascular events in patients with advanced kidney disease [abstract no: F-PO1902]","volume":"20","author":"Kendrick","year":"2009","journal-title":"Journal of the American Society of Nephrology"},{"key":"10.1002\/14651858.CD004683.pub4-BIB0024|cit24","first-page":"265A","article-title":"Low serum levels of 1,25-dihydroxyvitamin D, not 25-hydroxyvitamin D, is associated with all-cause mortality in chronic kidney disease [abstract no: TH-PO656]","volume":"20","author":"Kendrick","year":"2009","journal-title":"Journal of the American Society of Nephrology"},{"key":"10.1002\/14651858.CD004683.pub4-BIB0025|cit25","first-page":"263A","article-title":"Low serum levels of 1,25-dihydroxyvitamin D, not 25-hydroxyvitamin D, is associated with progression to dialysis in patients with advanced kidney disease [abstract no: TH-PO647]","volume":"20","author":"Kendrick","year":"2009","journal-title":"Journal of the American Society of Nephrology"},{"issue":"3","key":"10.1002\/14651858.CD004683.pub4-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1159\/000346941","article-title":"Low body mass index and dyslipidemia in dialysis patients linked to elevated plasma fibroblast growth factor 23","volume":"37","author":"Montford","year":"2013","journal-title":"American Journal of Nephrology"},{"issue":"9","key":"10.1002\/14651858.CD004683.pub4-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1016\/j.numecd.2012.07.002","article-title":"Adverse myocardial effects of B-vitamin therapy in subjects with chronic kidney disease and hyperhomocysteinaemia","volume":"23","author":"Rafeq","year":"2013 Sep","journal-title":"Nutrition Metabolism & Cardiovascular Diseases"},{"issue":"12","key":"10.1002\/14651858.CD004683.pub4-BIB0031|cit28","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1515\/CCLM.2007.335","article-title":"Homocysteine-lowering vitamin B treatment decreases cardiovascular events in hemodialysis patients","volume":"45","author":"Righetti","year":"2007","journal-title":"Clinical Chemistry & Laboratory Medicine"},{"issue":"4","key":"10.1002\/14651858.CD004683.pub4-BIB0028|cit29","first-page":"19","article-title":"Effects of folic acid treatment on homocysteine levels and vascular disease in hemodialysis patients","volume":"9","author":"Righetti","year":"2003","journal-title":"Medical Science Monitor"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD004683.pub4-BIB0029|cit30","first-page":"255","article-title":"Long-term effects of oral folic acid therapy on homocysteinemia and vascular disease in haemodialysis patients [abstract no: T237]","volume":"17","author":"Righetti","year":"2002","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"4","key":"10.1002\/14651858.CD004683.pub4-BIB0030|cit31","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1159\/000093680","article-title":"Homocysteine-lowering vitamin B treatment decreases cardiovascular events in hemodialysis patients","volume":"24","author":"Righetti","year":"2006","journal-title":"Blood Purification"},{"issue":"2","key":"10.1002\/14651858.CD004683.pub4-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1542-4758.2007.00171.x","article-title":"Uremic hyperhomocysteinemia: a randomized trial of folate treatment for the prevention of cardiovascular events","volume":"11","author":"Vianna","year":"2007","journal-title":"Hemodialysis International"},{"issue":"4","key":"10.1002\/14651858.CD004683.pub4-BIB0033|cit33","first-page":"A34","article-title":"Randomized trial of folic acid for homocysteine reduction in end-stage renal disease [abstract]","volume":"39","author":"Wrone","year":"2002","journal-title":"American Journal of Kidney Diseases"},{"issue":"2","key":"10.1002\/14651858.CD004683.pub4-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1097\/01.ASN.0000110181.64655.6C","article-title":"Randomized trial of folic acid for prevention of cardiovascular events in end-stage renal disease","volume":"15","author":"Wrone","year":"2004","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD004683.pub4-BIB0035|cit35","first-page":"A62","article-title":"The effect of n-acetylcysteine on homocysteine level in chronic hemodialysis patients: randomized control trial [abstract]","volume":"8","author":"Ali","year":"2003","journal-title":"Nephrology"},{"issue":"3","key":"10.1002\/14651858.CD004683.pub4-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.nut.2007.01.002","article-title":"Folic acid therapy reduces plasma homocysteine levels and improves plasma antioxidant capacity in hemodialysis patients","volume":"23","author":"Alvares Delfino","year":"2007","journal-title":"Nutrition"},{"issue":"7","key":"10.1002\/14651858.CD004683.pub4-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1093\/ndt\/gfl083","article-title":"Effects of folinic acid on forearm blood flow in patients with end-stage renal disease","volume":"21","author":"Anderson","year":"2006","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"4","key":"10.1002\/14651858.CD004683.pub4-BIB0038|cit38","first-page":"696","article-title":"Hyperhomocysteinaemia therapy in haemodialysis patients with combination of Vitamin B6, B12 and folic acid [abstract no: W467]","volume":"18","author":"Ardalan","year":"2003","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD004683.pub4-BIB0039|cit39","first-page":"509","article-title":"Hyperhomocysteinemia and its therapy in renal transplant recipients with combination of: Vit B6, Vit B12 and folic acid [abstract]","volume":"18","author":"Ardalan","year":"2003","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"3","key":"10.1002\/14651858.CD004683.pub4-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"168","DOI":"10.5414\/CNP60168","article-title":"Neither folic nor folinic acid normalize homocysteine levels in hemodialysis patients","volume":"60","author":"Armada","year":"2003","journal-title":"Clinical Nephrology"},{"issue":"3","key":"10.1002\/14651858.CD004683.pub4-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"186","DOI":"10.5414\/CNP59186","article-title":"The effect of vitamin B12 on total plasma homocysteine concentration in folate-replete hemodialysis patients","volume":"59","author":"Arnadottir","year":"2003","journal-title":"Clinical Nephrology"},{"issue":"8","key":"10.1002\/14651858.CD004683.pub4-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1093\/ndt\/gfn040","article-title":"Association between global leukocyte DNA methylation, renal function, carotid intima-media thickness and plasma homocysteine in patients with stage 2-4 chronic kidney disease","volume":"23","author":"Nanayakkara","year":"2008","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"1","key":"10.1002\/14651858.CD004683.pub4-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1053\/j.ajkd.2008.06.016","article-title":"Randomized placebo-controlled trial assessing a treatment strategy consisting of pravastatin, vitamin E, and homocysteine lowering on plasma asymmetric dimethylarginine concentration in mild to moderate CKD","volume":"53","author":"Nanayakkara","year":"2009","journal-title":"American Journal of Kidney Diseases"},{"issue":"5","key":"10.1002\/14651858.CD004683.pub4-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1111\/j.1523-1755.2005.00680.x","article-title":"Plasma asymmetric dimethylarginine (ADMA) concentration is independently associated with carotid intima-media thickness and plasma soluble vascular cell adhesion molecule-1 (sVCAM-1) concentration in patients with mild-to-moderate renal failure","volume":"68","author":"Nanayakkara","year":"2005","journal-title":"Kidney International"},{"issue":"12","key":"10.1002\/14651858.CD004683.pub4-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1001\/archinte.167.12.1262","article-title":"Effect of a treatment strategy consisting of pravastatin, vitamin E, and homocysteine lowering on carotid intima-media thickness, endothelial function, and renal function in patients with mild to moderate chronic kidney disease: results from the Anti-Oxidant Therapy in Chronic Renal Insufficiency (ATIC) Study","volume":"167","author":"Nanayakkara","year":"2007","journal-title":"Archives of Internal Medicine"},{"issue":"Abstracts","key":"10.1002\/14651858.CD004683.pub4-BIB0046|cit46","first-page":"367A","article-title":"Effect of an oxidative-stress-reducing strategy on carotid intima-media thickness, endothelial function and renal function in patients with mild-to-moderate chronic kidney disease [abstract no: F-PO145]","volume":"17","author":"Nanayakkara","year":"2006","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Abstracts","key":"10.1002\/14651858.CD004683.pub4-BIB0047|cit47","first-page":"367A","article-title":"Plasma adiponectin is inversely associated with renal function in patients with Stage 3 and 4 chronic kidney disease [abstract no: F-PO146]","volume":"17","author":"Nanayakkara","year":"2006","journal-title":"Journal of the American Society of Nephrology"},{"issue":"4","key":"10.1002\/14651858.CD004683.pub4-BIB0048|cit48","first-page":"325","article-title":"Mild-to-moderate renal impairment is associated with platelet activation: a cross-sectional study","volume":"70","author":"Thijs","year":"2008","journal-title":"Clinical Nephrology"},{"issue":"4","key":"10.1002\/14651858.CD004683.pub4-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"263","DOI":"10.5414\/CN107439","article-title":"Effect of a treatment strategy consisting of pravastatin, vitamin E, and homocysteine lowering on arterial compliance and distensibility in patients with mild-to-moderate chronic kidney disease","volume":"78","author":"Veringa","year":"2012","journal-title":"Clinical Nephrology"},{"issue":"5","key":"10.1002\/14651858.CD004683.pub4-BIB0050|cit50","first-page":"779","article-title":"Efficacy of folate and vitamin B12 in lowering homocysteine concentrations in hemodialysis patients","volume":"20","author":"Azadibakhsh","year":"2009","journal-title":"Saudi Journal of Kidney Diseases & Transplantation"},{"issue":"8","key":"10.1002\/14651858.CD004683.pub4-BIB0051|cit51","first-page":"49","article-title":"The effect of folate and vitamin B12 supplementation on homocysteine concentrations: a study in hemodialysis patients","volume":"65","author":"Azadibakhsh","year":"2007","journal-title":"Tehran University Medical Journal"},{"issue":"6","key":"10.1002\/14651858.CD004683.pub4-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1053\/j.jrn.2009.06.005","article-title":"Effect of over-the-counter fish-oil administration on plasma Lp(a) levels in an end-stage renal disease population","volume":"19","author":"Beavers","year":"2009","journal-title":"Journal of Renal Nutrition"},{"issue":"4","key":"10.1002\/14651858.CD004683.pub4-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1111\/j.1440-1797.2008.00934.x","article-title":"Omega-3 fatty acid supplementation and total homocysteine levels in end-stage renal disease patients","volume":"13","author":"Beavers","year":"2008","journal-title":"Nephrology"},{"issue":"15","key":"10.1002\/14651858.CD004683.pub4-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1161\/01.CIR.0000014417.95833.1D","article-title":"Does oral folic acid lower total homocysteine levels and improve endothelial function in children with chronic renal failure?","volume":"105","author":"Bennett-Richards","year":"2002","journal-title":"Circulation"},{"issue":"8","key":"10.1002\/14651858.CD004683.pub4-BIB0055|cit55","first-page":"C167","article-title":"Does oral folic acid lower total homocystine levels and improve endothelial function in children with CRF? [abstract]","volume":"16","author":"Bennett-Richards","year":"2001","journal-title":"Pediatric Nephrology"},{"issue":"1","key":"10.1002\/14651858.CD004683.pub4-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/ki.1996.19","article-title":"High dose-B-vitamin treatment of hyperhomocysteinemia in dialysis patients","volume":"49","author":"Bostom","year":"1996","journal-title":"Kidney International"},{"issue":"24","key":"10.1002\/14651858.CD004683.pub4-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"2829","DOI":"10.1161\/01.CIR.101.24.2829","article-title":"Controlled comparison of L-5-methyltetrahydrofolate versus folic acid for the treatment of hyperhomocysteinemia in hemodialysis patients.[Erratum appears in Circulation 2000 Aug 1;102(5):598]","volume":"101","author":"Bostom","year":"2000","journal-title":"Circulation"},{"issue":"Sept","key":"10.1002\/14651858.CD004683.pub4-BIB0058|cit58","first-page":"257A","article-title":"Reduced folates are an expensive treatment for hyperhomocysteinemia in hemodialysis patients with no greater efficacy than folic acid: results of a controlled comparison study [abstract]","volume":"11","author":"Bostom","year":"2000","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Suppl 78","key":"10.1002\/14651858.CD004683.pub4-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"S246","DOI":"10.1046\/j.1523-1755.2001.59780246.x","article-title":"Treatment of hyperhomocysteinemia in hemodialysis patients and renal transplant recipients","volume":"59","author":"Bostom","year":"2001","journal-title":"Kidney International - Supplement"},{"issue":"10","key":"10.1002\/14651858.CD004683.pub4-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1097\/00007890-200005270-00029","article-title":"Treatment of mild hyperhomocysteinemia in renal transplant recipients versus hemodialysis patients","volume":"69","author":"Bostom","year":"2000","journal-title":"Transplantation"},{"issue":"3","key":"10.1002\/14651858.CD004683.pub4-BIB0061|cit61","first-page":"A79","article-title":"Randomised placebo controlled clinical trial of supplementary folic acid in CRF [abstract]","volume":"5","author":"Branley","year":"2000","journal-title":"Nephrology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD004683.pub4-BIB0062|cit62","first-page":"30","article-title":"Improved hyperhomocysteinemia in hemodialysed ESRD-patients by intravenous folate or folinic acid: a randomized controlled trial [abstract no: O100]","volume":"17","author":"Brensing","year":"2002","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Nov","key":"10.1002\/14651858.CD004683.pub4-BIB0063|cit63","first-page":"766A","article-title":"Vitamin B12 and folic-acid as intravenous high-dose vitamin therapy for hyperhomocysteinemia in hemodialysed ESRD-patients: data of a prospective randomized controlled study [abstract no: SU-PO1048]","volume":"14","author":"Brensing","year":"2003","journal-title":"Journal of the American Society of Nephrology"},{"issue":"8","key":"10.1002\/14651858.CD004683.pub4-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1185\/030079907X218077","article-title":"Effects of folic acid and vitamin B complex on serum C-reactive protein and albumin levels in stable hemodialysis patients","volume":"23","author":"Chang","year":"2007","journal-title":"Current Medical Research & Opinion"},{"issue":"4","key":"10.1002\/14651858.CD004683.pub4-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1080\/08860220902780010","article-title":"Pharmacological dose of vitamin B12 is as effective as low-dose folinic acid in correcting hyperhomocysteinemia of hemodialysis patients","volume":"31","author":"Chiu","year":"2009","journal-title":"Renal Failure"},{"issue":"6","key":"10.1002\/14651858.CD004683.pub4-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1159\/000142363","article-title":"5-methyltetrahydrofolate administration is associated with prolonged survival and reduced inflammation in ESRD patients","volume":"28","author":"Cianciolo","year":"2008","journal-title":"American Journal of Nephrology"},{"issue":"3","key":"10.1002\/14651858.CD004683.pub4-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1159\/000207197","article-title":"Mesna for the treatment of hyperhomocysteinemia in hemodialysis patients","volume":"27","author":"Cutler","year":"2009","journal-title":"Blood Purification"},{"issue":"1","key":"10.1002\/14651858.CD004683.pub4-BIB0068|cit68","first-page":"51","article-title":"Hyperhomocysteinemia and alternate vitamin supplementation","volume":"24","author":"Angelis","year":"2007","journal-title":"Giornale Italiano di Nefrologia"},{"issue":"1","key":"10.1002\/14651858.CD004683.pub4-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1007\/s10157-014-0961-6","article-title":"Influence of dialysis techniques and alternate vitamin supplementation on homocysteine levels in patients with known MTHFR genotypes","volume":"19","author":"Dessi","year":"2015","journal-title":"Clinical & Experimental Nephrology"},{"issue":"Suppl 5","key":"10.1002\/14651858.CD004683.pub4-BIB0070|cit70","first-page":"v106","article-title":"Optimization of a therapy schedule with folinic acid to treat hyperhomocysteinemia in patients on hemodialysis [abstract no: SP261]","volume":"20","author":"Pozo","year":"2005","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"3","key":"10.1002\/14651858.CD004683.pub4-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1159\/000046089","article-title":"Folate supplementation in peritoneal dialysis patients with normal erythrocyte folate: effect on plasma homocysteine","volume":"89","author":"Vecchi","year":"2001","journal-title":"Nephron"},{"issue":"12","key":"10.1002\/14651858.CD004683.pub4-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"2596","DOI":"10.1093\/ndt\/gfg437","article-title":"Effect of dialyser membrane pore size on plasma homocysteine levels in haemodialysis patients","volume":"18","author":"Vriese","year":"2003","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"2","key":"10.1002\/14651858.CD004683.pub4-BIB0073|cit73","first-page":"108","article-title":"Response of hyperhomocysteinemia to folic acid supplementation in patients with end-stage renal disease","volume":"51","author":"Dierkes","year":"1999","journal-title":"Clinical Nephrology"},{"issue":"2","key":"10.1002\/14651858.CD004683.pub4-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S1051-2276(01)31274-8","article-title":"Homocysteine lowering effect of different multivitamin preparations in patients with end-stage renal disease","volume":"11","author":"Dierkes","year":"2001","journal-title":"Journal of Renal Nutrition"},{"key":"10.1002\/14651858.CD004683.pub4-BIB0075|cit75","first-page":"80A","article-title":"Vitamin therapy for homocysteine accelerates loss of renal function in diabetic kidney disease [abstract no: SA-FC343]","volume":"20","author":"House","year":"2009","journal-title":"Journal of the American Society of Nephrology"},{"issue":"16","key":"10.1002\/14651858.CD004683.pub4-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1001\/jama.2010.490","article-title":"Effect of B-vitamin therapy on progression of diabetic nephropathy: a randomized controlled trial","volume":"303","author":"House","year":"2010","journal-title":"JAMA"},{"issue":"Abstracts Issue","key":"10.1002\/14651858.CD004683.pub4-BIB0077|cit77","first-page":"943A","article-title":"The effect of IV administration of sodium 2,3-dimercaptopropane-1-sulfonate (DMPS) and 8-week high-dosed IV vitamin B therapy on total plasma homocysteine (tHcy) in patients undergoing chronic hemodialysis (HD) [abstract no: PUB584]","volume":"19","author":"Dobronravov","year":"2008","journal-title":"Journal of the American Society of Nephrology"},{"issue":"5","key":"10.1002\/14651858.CD004683.pub4-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1093\/ndt\/17.5.865","article-title":"Hyperhomocysteinaemia therapy in haemodialysis patients: folinic versus folic acid in combination with vitamin B6 and B12","volume":"17","author":"Ducloux","year":"2002","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Program & Abstr","key":"10.1002\/14651858.CD004683.pub4-BIB0079|cit79","first-page":"354A","article-title":"Hyperhomocysteinemia therapy in hemodialysis (HD) patients: folinic versus folic acid in combination with vitamin B6 and B12 [abstract]","volume":"12","author":"Ducloux","year":"2001","journal-title":"Journal of the American Society of Nephrology"},{"issue":"7","key":"10.1002\/14651858.CD004683.pub4-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1053\/meta.2002.32800","article-title":"Hydroxocobalamin reduces hyperhomocysteinemia in end-stage renal disease","volume":"51","author":"Elian","year":"2002","journal-title":"Metabolism: Clinical & Experimental"},{"issue":"2","key":"10.1002\/14651858.CD004683.pub4-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1053\/ajkd.2003.50054","article-title":"The effect of N-acetylcysteine on plasma total homocysteine levels in hemodialysis: a randomized, controlled study","volume":"41","author":"Friedman","year":"2003","journal-title":"American Journal of Kidney Diseases"},{"issue":"2","key":"10.1002\/14651858.CD004683.pub4-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1046\/j.1523-1755.2003.00134.x","article-title":"The effect of PMMA-based protein-leaking dialyzers on plasma homocysteine levels","volume":"64","author":"Galli","year":"2003","journal-title":"Kidney International"},{"issue":"2","key":"10.1002\/14651858.CD004683.pub4-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1111\/j.1523-1755.2005.67138.x","article-title":"Glycoxidation and inflammatory markers in patients on treatment with PMMA-based protein-leaking dialyzers","volume":"67","author":"Galli","year":"2005","journal-title":"Kidney International"},{"issue":"4","key":"10.1002\/14651858.CD004683.pub4-BIB0084|cit84","first-page":"522","article-title":"Controlled trials of very high dose folic acid, vitamins B12 and B6, intravenous folinic acid and serine for treatment of hyperhomocysteinemia in ESRD","volume":"16","author":"Gonin","year":"2003","journal-title":"Journal of Nephrology"},{"issue":"Sept","key":"10.1002\/14651858.CD004683.pub4-BIB0085|cit85","first-page":"269A","article-title":"A double-blind, controlled study of folate and vitamin therapy for hyperhomocysteinemia in hemodialysis [abstract]","volume":"11","author":"Gonin","year":"2000","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Program & Abstr","key":"10.1002\/14651858.CD004683.pub4-BIB0086|cit86","first-page":"356A","article-title":"Evaluation of folinic acid and serine in hyperhomocysteinemia in ESRD: a prospective placebo-controlled randomized study [abstract]","volume":"12","author":"Gonin","year":"2001","journal-title":"Journal of the American Society of Nephrology"},{"issue":"4","key":"10.1002\/14651858.CD004683.pub4-BIB0087|cit87","first-page":"522","article-title":"Controlled trials of very high dose folic acid, vitamins B12 and B6, intravenous folinic acid and serine for treatment of hyperhomocysteinemia in ESRD","volume":"16","author":"Gonin","year":"2003","journal-title":"Journal of Nephrology"},{"issue":"Sept","key":"10.1002\/14651858.CD004683.pub4-BIB0088|cit88","first-page":"148A","article-title":"Comparison of intravenous folinic acid with intravenous folic acid for the treatment of hyperhomocysteinemia in hemodialysis patients. A randomized, double blinded trial [abstract]","volume":"11","author":"Hagen","year":"2000","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Program & Abstr","key":"10.1002\/14651858.CD004683.pub4-BIB0089|cit89","first-page":"483A","article-title":"Effect of intravenous folic acid or folinic acid therapy on mean arterial pressure and pulse pressure in hemodialysis patients [abstract]","volume":"12","author":"Hagen","year":"2001","journal-title":"Journal of the American Society of Nephrology"},{"issue":"4","key":"10.1002\/14651858.CD004683.pub4-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/S0272-6386(01)80125-6","article-title":"Efficacy of folinic versus folic acid for the correction of hyperhomocysteinemia in hemodialysis patients","volume":"37","author":"Hauser","year":"2001","journal-title":"American Journal of Kidney Diseases"},{"issue":"3","key":"10.1002\/14651858.CD004683.pub4-BIB0091|cit91","first-page":"155","article-title":"Homocyst(e)ine metabolism in hemodialysis patients treated with vitamins B6, B12 and folate","volume":"200","author":"Henning","year":"2001","journal-title":"Research in Experimental Medicine"},{"issue":"6","key":"10.1002\/14651858.CD004683.pub4-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.metabol.2005.01.034","article-title":"Cobalamin dose regimen for maximum homocysteine reduction in end-stage renal disease","volume":"54","author":"Hoffer","year":"2005","journal-title":"Metabolism: Clinical & Experimental"},{"issue":"10","key":"10.1002\/14651858.CD004683.pub4-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1016\/j.metabol.2005.04.027","article-title":"Comparative effects of hydroxocobalamin and cyanocobalamin on plasma homocysteine concentrations in end-stage renal disease","volume":"54","author":"Hoffer","year":"2005","journal-title":"Metabolism: Clinical & Experimental"},{"issue":"1","key":"10.1002\/14651858.CD004683.pub4-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S0828-282X(06)70238-0","article-title":"Rationale, design and baseline characteristics of a large, simple, randomized trial of combined folic acid and vitamins B6 and B12 in high-risk patients: the Heart Outcomes Prevention Evaluation (HOPE)-2 trial","volume":"22","author":"Lonn","year":"2006","journal-title":"Canadian Journal of Cardiology"},{"issue":"15","key":"10.1002\/14651858.CD004683.pub4-BIB0095|cit95","first-page":"1567","article-title":"Homocysteine lowering with folic acid and B vitamins in vascular disease.[erratum appears in N Engl J Med. 2006 Aug 17;355(7):746]","volume":"354","author":"Lonn","year":"2006","journal-title":"New England Journal of Medicine"},{"issue":"2","key":"10.1002\/14651858.CD004683.pub4-BIB0096|cit96","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1093\/ndt\/gfm485","article-title":"Homocysteine lowering with folic acid and B vitamins in people with chronic kidney disease--results of the renal Hope-2 study","volume":"23","author":"Mann","year":"2008","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"11","key":"10.1002\/14651858.CD004683.pub4-BIB0097|cit97","doi-asserted-by":"crossref","first-page":"761","DOI":"10.7326\/0003-4819-146-11-200706050-00157","article-title":"Homocysteine-lowering therapy and risk for venous thromboembolism: a randomized trial.[Summary for patients in Ann Intern Med. 2007 Jun 5;146(11):I22; PMID: 17470823]","volume":"146","author":"Ray","year":"2007","journal-title":"Annals of Internal Medicine"},{"issue":"7","key":"10.1002\/14651858.CD004683.pub4-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1093\/ndt\/gfn066","article-title":"Hopeful for a second HOPE-2 post hoc analysis","volume":"23","author":"Righetti","year":"2008","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"4","key":"10.1002\/14651858.CD004683.pub4-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1161\/STROKEAHA.108.529503","article-title":"Homocysteine-lowering therapy and stroke risk, severity, and disability: additional findings from the HOPE 2 trial","volume":"40","author":"Saposnik","year":"2009","journal-title":"Stroke"},{"issue":"19","key":"10.1002\/14651858.CD004683.pub4-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1001\/archinte.167.19.2136","article-title":"Randomized clinical trial of homocysteine level lowering therapy and fractures","volume":"167","author":"Sawka","year":"2007","journal-title":"Archives of Internal Medicine"},{"issue":"Program & Abstr","key":"10.1002\/14651858.CD004683.pub4-BIB0101|cit101","first-page":"209A","article-title":"Larger intradialytic effect of high flux vs low flux polysulfone on homocysteine levels, but not on lipids or apo AI\/CIII ratio [abstract]","volume":"12","author":"House","year":"2001","journal-title":"Journal of the American Society of Nephrology"},{"issue":"1","key":"10.1002\/14651858.CD004683.pub4-BIB0102|cit102","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1097\/00002480-199901000-00021","article-title":"Effect of multivitamins on plasma homocysteine and folate levels in patients on hemodialysis","volume":"45","author":"House","year":"1999","journal-title":"ASAIO Journal"},{"issue":"Program & Abstr","key":"10.1002\/14651858.CD004683.pub4-BIB0103|cit103","first-page":"168A","article-title":"Impact of methylenetetrahydrofolate reductase (MTHFR) genotype on folate status and homocysteine (hcy) in hemodialysis patients [abstract]","volume":"10","author":"House","year":"1999","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Program & Abstr","key":"10.1002\/14651858.CD004683.pub4-BIB0104|cit104","first-page":"211A","article-title":"Effect of high flux vs low flux hemodialysis on homocysteine, lipoprotein(a) and lipid profiles: a prospective randomized trial [abstract]","volume":"9","author":"House","year":"1998","journal-title":"Journal of the American Society of Nephrology"},{"issue":"7","key":"10.1002\/14651858.CD004683.pub4-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1093\/ndt\/15.7.1029","article-title":"Randomized trial of high-flux vs low-flux haemodialysis: effects on homocysteine and lipids","volume":"15","author":"House","year":"2000","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"4","key":"10.1002\/14651858.CD004683.pub4-BIB0106|cit106","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/S0272-6386(04)00938-2","article-title":"Dimercaptosuccinic acid for the treatment of hyperhomocysteinemia in hemodialysis patients: a placebo-controlled, double-blind, randomized trial","volume":"44","author":"House","year":"2004","journal-title":"American Journal of Kidney Diseases"},{"issue":"5","key":"10.1002\/14651858.CD004683.pub4-BIB0107|cit107","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1053\/j.jrn.2009.01.020","article-title":"Effects of soy consumption on oxidative stress, blood homocysteine, coagulation factors, and phosphorus in peritoneal dialysis patients","volume":"19","author":"Imani","year":"2009","journal-title":"Journal of Renal Nutrition"},{"issue":"6","key":"10.1002\/14651858.CD004683.pub4-BIB0108|cit108","doi-asserted-by":"crossref","first-page":"611","DOI":"10.3747\/pdi.2009.00161","article-title":"Effects of soy consumption on serum lipids and apoproteins in peritoneal dialysis patients: a randomized controlled trial","volume":"30","author":"Tabibi","year":"2010","journal-title":"Peritoneal Dialysis International"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD004683.pub4-BIB0109|cit109","first-page":"A69","article-title":"Vitamin B12 is effective in the treatment of hyperhomocysteinaemia in patients with ESRD [abstract no: 58]","volume":"8","author":"Isbel","year":"2003","journal-title":"Nephrology"},{"key":"10.1002\/14651858.CD004683.pub4-BIB0110|cit110","unstructured":"ISRCTN22151635 Assessment of the lipid lowering agents on plasma homocysteine concentration and renal function controlled-trials.com\/ISRCTN22151635"},{"issue":"Program & Abstr","key":"10.1002\/14651858.CD004683.pub4-BIB0111|cit111","first-page":"357A","article-title":"Intravenous folinic acid versus oral folic acid for the treatment of hyperhomocysteinemia in hemodialysis patients [abstract]","volume":"12","author":"Jara","year":"2001","journal-title":"Journal of the American Society of Nephrology"},{"issue":"4","key":"10.1002\/14651858.CD004683.pub4-BIB0112|cit112","doi-asserted-by":"crossref","first-page":"A57","DOI":"10.1053\/j.ajkd.2008.02.126","article-title":"Homocysteine lowering effect of adsorptive dialysis membranes: a multicenter, randomized, open study [abstract no: 118]","volume":"51","author":"Kazory","year":"2008","journal-title":"American Journal of Kidney Diseases"},{"issue":"3","key":"10.1002\/14651858.CD004683.pub4-BIB0113|cit113","doi-asserted-by":"crossref","first-page":"191","DOI":"10.5414\/CNP61191","article-title":"Influence of hemodialysis membrane permeability on serum levels of advanced glycation end products (AGEs) and homocysteine metabolites","volume":"61","author":"Klemm","year":"2004","journal-title":"Clinical Nephrology"},{"issue":"3","key":"10.1002\/14651858.CD004683.pub4-BIB0114|cit114","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1159\/000329727","article-title":"Effects of marine omega-3 fatty acids on serum systemic and vascular inflammation markers and oxidative stress in hemodialysis patients","volume":"58","author":"Kooshki","year":"2011","journal-title":"Annals of Nutrition & Metabolism"},{"issue":"9","key":"10.1002\/14651858.CD004683.pub4-BIB0115|cit115","doi-asserted-by":"crossref","first-page":"892","DOI":"10.3109\/0886022X.2011.605536","article-title":"Effects of omega-3 fatty acids on serum lipids, lipoprotein (a), and hematologic factors in hemodialysis patients","volume":"33","author":"Kooshki","year":"2011","journal-title":"Renal Failure"},{"issue":"5","key":"10.1002\/14651858.CD004683.pub4-BIB0116|cit116","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1093\/ndt\/17.5.916","article-title":"Efficacy of methylcobalamin on lowering total homocysteine plasma concentrations in haemodialysis patients receiving high-dose folic acid supplementation","volume":"17","author":"Koyama","year":"2002","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Suppl 6","key":"10.1002\/14651858.CD004683.pub4-BIB0117|cit117","first-page":"vi339","article-title":"Short term regimen of homocysteine-lowering therapy reduces serum concentration of asymmetric dimethylarginine in patients on chronic hemodialysis [abstract no: SaP317]","volume":"22","author":"Koyama","year":"2007","journal-title":"Nephrology Dialysis Transplantation"},{"key":"10.1002\/14651858.CD004683.pub4-BIB0118|cit118","first-page":"798A","article-title":"Co-administration of methylcobalamin and folic acid normalizes hyperhomocysteinemia and reduces arterial stiffness in hemodialsyis patients [abstract no: PUB074]","volume":"16","author":"Koyama","year":"2005","journal-title":"Journal of the American Society of Nephrology"},{"issue":"6","key":"10.1002\/14651858.CD004683.pub4-BIB0119|cit119","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1053\/j.ajkd.2009.12.035","article-title":"Randomized controlled trial of the effect of short-term coadministration of methylcobalamin and folate on serum ADMA concentration in patients receiving long-term hemodialysis","volume":"55","author":"Koyama","year":"2010","journal-title":"American Journal of Kidney Diseases"},{"issue":"Oct","key":"10.1002\/14651858.CD004683.pub4-BIB0120|cit120","first-page":"377A","article-title":"Normalization of plasma homocystein (Hcy) levels in hyperhomocysteinemic hemodialysis patients by intravenous dosage of vitamins B6, B12 and folic acid. [abstract no SA-PO345]","volume":"15","author":"Kuhlmann","year":"2004","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Abstracts Issue","key":"10.1002\/14651858.CD004683.pub4-BIB0121|cit121","first-page":"516A","article-title":"Impact of folic acid on homocysteine levels in haemodialysis patients, a randomized double blinded placebo controlled cross over trial [abstract no: SA-PO788]","volume":"18","author":"Kumar","year":"2007","journal-title":"Journal of the American Society of Nephrology"},{"issue":"6","key":"10.1002\/14651858.CD004683.pub4-BIB0122|cit122","first-page":"A87","article-title":"Intravenous methylcobalamin further improves hyperhomocysteinemia in hemodialysis patients under maintenance folic acid therapy: role of methyletetrahydrofolate reductase (mthfr) genotype [abstract]","volume":"16","author":"Kuo","year":"2001","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD004683.pub4-BIB0123|cit123","first-page":"A408","article-title":"Rapid progression of myocardial ischaemia in patients with chronic kidney disease is not altered by risk factor modification [abstract no: PS107]","volume":"10","author":"Isbel","year":"2005","journal-title":"Nephrology"},{"issue":"3","key":"10.1002\/14651858.CD004683.pub4-BIB0124|cit124","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.ahj.2005.06.017","article-title":"Increased targeting of cardiovascular risk factors in patients with chronic kidney disease does not improve atheroma burden or cardiovascular function","volume":"151","author":"Isbel","year":"2006","journal-title":"American Heart Journal"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD004683.pub4-BIB0125|cit125","first-page":"A1","article-title":"Aggressive intervention in traditional cardiovascular risk factors in patients with chronic renal failure does not improve atheroma burden, cardiovascular function or outcome [abstract]","volume":"9","author":"Isbel","year":"2004","journal-title":"Nephrology"},{"issue":"4","key":"10.1002\/14651858.CD004683.pub4-BIB0126|cit126","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1111\/j.1440-1797.2007.00804.x","article-title":"Metabolic syndrome in severe chronic kidney disease: Prevalence, predictors, prognostic significance and effects of risk factor modification","volume":"12","author":"Johnson","year":"2007","journal-title":"Nephrology"},{"issue":"10","key":"10.1002\/14651858.CD004683.pub4-BIB0127|cit127","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1136\/hrt.2005.074393","article-title":"Effect of aggressive risk factor modification on cardiac events and myocardial ischaemia in patients with chronic kidney disease","volume":"92","author":"Rakhit","year":"2006","journal-title":"Heart"},{"issue":"Oct","key":"10.1002\/14651858.CD004683.pub4-BIB0128|cit128","first-page":"376A","article-title":"Treatment of hyperhomocysteinemia in hemodialysis patients reduce progressive atherosclerosis: a long-term controlled study [abstract no: SA-PO343]","volume":"15","author":"Libetta","year":"2004","journal-title":"Journal of the American Society of Nephrology"},{"key":"10.1002\/14651858.CD004683.pub4-BIB0129|cit129","unstructured":"Libetta C Corbetta R Zucchi M Gori E Villa G Sepe V Long-term treatment of hyperhomocysteinemia prevents carotid artery atherosclerosis in haemodialysed patients [abstract] 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15-18; Lisbon, Portugal 2004 4"},{"issue":"Oct","key":"10.1002\/14651858.CD004683.pub4-BIB0130|cit130","first-page":"377A","article-title":"Vitamins supplementation effectiveness on hyperhomocysteinemia in hemodialyzed patients: a two-year single-blind randomized study [abstract no: SA-PO344]","volume":"15","author":"Libetta","year":"2004","journal-title":"Journal of the American Society of Nephrology"},{"key":"10.1002\/14651858.CD004683.pub4-BIB0131|cit131","unstructured":"Libetta C Villa G Gori E Zucchi M Sepe V Pisacco P Effect of folate or folate plus vitamins B6 and B12 on hyperhomocysteinemia in hemodialyzed patients: a 2-year controlled randomized study [abstract] 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15-18; Lisbon, Portugal 2004 126"},{"issue":"1","key":"10.1002\/14651858.CD004683.pub4-BIB0132|cit132","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1177\/0148607110371807","article-title":"Effect of intravenous omega-3 fatty acid infusion and hemodialysis on fatty acid composition of free fatty acids and phospholipids in patients with end-stage renal disease","volume":"35","author":"Madsen","year":"2011","journal-title":"Jpen: Journal of Parenteral & Enteral Nutrition"},{"issue":"2","key":"10.1002\/14651858.CD004683.pub4-BIB0133|cit133","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1053\/meta.2003.50022","article-title":"Vitamin B12 decreases, but does not normalize, homocysteine and methylmalonic acid in end-stage renal disease: a link with glycine metabolism and possible explanation of hyperhomocysteinemia in end-stage renal disease","volume":"52","author":"Hyndman","year":"2003","journal-title":"Metabolism: Clinical & Experimental"},{"issue":"3","key":"10.1002\/14651858.CD004683.pub4-BIB0134|cit134","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1046\/j.1523-1755.2001.0590031103.x","article-title":"Oral vitamin B(12) and high-dose folic acid in hemodialysis patients with hyper-homocyst(e)inemia","volume":"59","author":"Manns","year":"2001","journal-title":"Kidney International"},{"issue":"Suppl 5","key":"10.1002\/14651858.CD004683.pub4-BIB0135|cit135","first-page":"v307","article-title":"Hyperhomocysteinemia therapy in haemodialysis patients: folinic versus folic acid in combination with vitamin B6 and B12 [abstract no: MP318]","volume":"20","author":"Abolghasemi","year":"2005","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD004683.pub4-BIB0136|cit136","first-page":"A283","article-title":"Hyperhomocysteinemia therapy in hemodialysis patients: folinic versus folic acid in combination with vitamin B6 and B12 [abstract no: W-PO40014]","volume":"10","author":"Mazdeh","year":"2005","journal-title":"Nephrology"},{"issue":"3","key":"10.1002\/14651858.CD004683.pub4-BIB0137|cit137","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1159\/000045664","article-title":"A controlled trial of the effect of folate supplements on homocysteine, lipids and hemorheology in end-stage renal disease","volume":"85","author":"McGregor","year":"2000","journal-title":"Nephron"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD004683.pub4-BIB0138|cit138","first-page":"A16","article-title":"Plasma homocysteine levels with standard high flux haemodialysis compared with FX class dialysers [abstract]","volume":"9","author":"Mudge","year":"2004","journal-title":"Nephrology"},{"issue":"10","key":"10.1002\/14651858.CD004683.pub4-BIB0139|cit139","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1093\/ndt\/gfh987","article-title":"Randomized trial of FX high flux vs standard high flux dialysis for homocysteine clearance","volume":"20","author":"Mudge","year":"2005","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD004683.pub4-BIB0140|cit140","first-page":"700","article-title":"Reduced folates have an anti-inflammatory effect in hemodialysis patients [abstract]","volume":"18","author":"Mueller","year":"2003","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"September, Prog","key":"10.1002\/14651858.CD004683.pub4-BIB0141|cit141","first-page":"38A","article-title":"Effect of folate therapy on the inflammatory burden in hemodialysis patients [abstract no: SA-FC185]","volume":"13","author":"Mueller","year":"2002","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Program & Abstr","key":"10.1002\/14651858.CD004683.pub4-BIB0142|cit142","first-page":"360A","article-title":"Effect of oral substitution of reduced folates on homocysteine, neopterin, and lipid levels in patients treated with hemodialysis [abstract]","volume":"12","author":"Mueller","year":"2001","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Program & Abstr","key":"10.1002\/14651858.CD004683.pub4-BIB0143|cit143","first-page":"734A","article-title":"L-methionine loading test for the prediction of increased total homocysteine levels due to long term l-methionine treatment [abstract]","volume":"12","author":"Muller","year":"2001","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD004683.pub4-BIB0144|cit144","first-page":"699","article-title":"Methylenetetrahydrofolate reductase (MTHFR) gene polymorphism influences the efficacy of folic acid (FA) and vitamin B12 (B12) on hyperhomocyteinemia in hemodialysis (HD) patients [abstract]","volume":"18","author":"Nakamura","year":"2003","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"4","key":"10.1002\/14651858.CD004683.pub4-BIB0145|cit145","first-page":"213","article-title":"Comparative study of response to treatment with supraphysiologic doses of B-vitamins in hyperhomocysteinemic hemodialysis patients","volume":"6","author":"Nakhoul","year":"2004","journal-title":"Israel Medical Association Journal - Imaj"},{"issue":"Sept","key":"10.1002\/14651858.CD004683.pub4-BIB0146|cit146","first-page":"295A","article-title":"Folic acid and varying doses of B-vitamines in the treatment of hyperhomocystinemia in hemodialysis patients [abstract]","volume":"11","author":"Plawner","year":"2000","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Abstracts","key":"10.1002\/14651858.CD004683.pub4-BIB0147|cit147","first-page":"270A","article-title":"Effect of N-acetylcysteine supplementation on inflammatory and oxidative stress markers in peritoneal dialysis patients: a randomized placebo controlled study [abstract no: F-PO769]","volume":"18","author":"Nascimento","year":"2007","journal-title":"Journal of the American Society of Nephrology"},{"issue":"3","key":"10.1002\/14651858.CD004683.pub4-BIB0148|cit148","doi-asserted-by":"crossref","first-page":"336","DOI":"10.3747\/pdi.2009.00073","article-title":"Effect of oral N-acetylcysteine treatment on plasma inflammatory and oxidative stress markers in peritoneal dialysis patients: a placebo-controlled study","volume":"30","author":"Nascimento","year":"2010","journal-title":"Peritoneal Dialysis International"},{"issue":"5","key":"10.1002\/14651858.CD004683.pub4-BIB0149|cit149","doi-asserted-by":"crossref","first-page":"279","DOI":"10.5414\/CN108285","article-title":"n-3 polyunsaturated fatty acids and adiponectin in patients with end-stage renal disease","volume":"83","author":"Harving","year":"2015","journal-title":"Clinical Nephrology"},{"issue":"6","key":"10.1002\/14651858.CD004683.pub4-BIB0150|cit150","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1017\/S0007114511003771","article-title":"Marine n-3 fatty acids, atrial fibrillation and QT interval in haemodialysis patients","volume":"107","author":"Kirkegaard","year":"2012","journal-title":"British Journal of Nutrition"},{"issue":"8","key":"10.1002\/14651858.CD004683.pub4-BIB0151|cit151","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.nutres.2010.07.004","article-title":"The content of docosahexaenoic acid in serum phospholipid is inversely correlated with plasma homocysteine levels in patients with end-stage renal disease","volume":"30","author":"Rasmussen","year":"2010","journal-title":"Nutrition Research"},{"key":"10.1002\/14651858.CD004683.pub4-BIB0152|cit152","first-page":"466A","article-title":"Omacor as secondary prevention against cardiovascular disease in patients undergoing chronic hemodialysis: a randomised, placebo controlled intervention study [abstract no: F-PO606]","volume":"16","author":"Svensson","year":"2005","journal-title":"Journal of the American Society of Nephrology"},{"issue":"4","key":"10.1002\/14651858.CD004683.pub4-BIB0153|cit153","first-page":"459","article-title":"The effect of n-3 fatty acids on levels of methylarginines in patients with end-stage renal disease","volume":"23","author":"Svensson","year":"2010","journal-title":"Journal of Nephrology"},{"issue":"4","key":"10.1002\/14651858.CD004683.pub4-BIB0155|cit154","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1053\/j.jrn.2007.02.004","article-title":"The effect of n-3 fatty acids on heart rate variability in patients treated with chronic hemodialysis","volume":"17","author":"Svensson","year":"2007","journal-title":"Journal of Renal Nutrition"},{"issue":"9","key":"10.1002\/14651858.CD004683.pub4-BIB0156|cit155","doi-asserted-by":"crossref","first-page":"2918","DOI":"10.1093\/ndt\/gfn180","article-title":"The effect of n-3 fatty acids on lipids and lipoproteins in patients treated with chronic haemodialysis: a randomized placebo-controlled intervention study","volume":"23","author":"Svensson","year":"2008","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"4","key":"10.1002\/14651858.CD004683.pub4-BIB0154|cit156","doi-asserted-by":"crossref","first-page":"780","DOI":"10.2215\/CJN.00630206","article-title":"N-3 fatty acids as secondary prevention against cardiovascular events in patients who undergo chronic hemodialysis: A randomized, placebo-controlled intervention trial","volume":"1","author":"Svensson","year":"2006","journal-title":"Clinical Journal of the American Society of Nephrology: CJASN"},{"issue":"4","key":"10.1002\/14651858.CD004683.pub4-BIB0157|cit157","first-page":"227","article-title":"Different doses of oral folic acid for homocysteine-lowering therapy in patients on hemodialysis: a randomized controlled trial.[Erratum appears in Iran J Kidney Dis. 2010 Jan;4(1):88 Note: Salimi, Ashraf [added]; Asgari, Mojgan [added]]","volume":"3","author":"Ossareh","year":"2009","journal-title":"Iranian Journal of Kidney Diseases"},{"issue":"1-3","key":"10.1002\/14651858.CD004683.pub4-BIB0158|cit158","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s12011-013-9639-2","article-title":"Effects of zinc supplement on plasma homocysteine level in end-stage renal disease patients: a double-blind randomized clinical trial","volume":"153","author":"Pakfetrat","year":"2013","journal-title":"Biological Trace Element Research"},{"issue":"1","key":"10.1002\/14651858.CD004683.pub4-BIB0159|cit159","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1373\/clinchem.2005.056119","article-title":"Effects of folic acid before and after vitamin B12 on plasma homocysteine concentrations in hemodialysis patients with known MTHFR genotypes","volume":"52","author":"Pastore","year":"2006","journal-title":"Clinical Chemistry"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD004683.pub4-BIB0160|cit160","first-page":"A288","article-title":"A prospective, randomized, placebo-controlled study to evaluate the effect of combined treatment of folic acid and intravenous B-complex vitamins on hyperhomocysteinemia in hemodialysis patients [abstract no: W-PO40032]","volume":"10","author":"Peng","year":"2005","journal-title":"Nephrology"},{"key":"10.1002\/14651858.CD004683.pub4-BIB0161|cit161","unstructured":"Polkinghorne KR Zoungas S Branley P Villanueva E McNeil JJ Atkins RC A randomised placebo controlled trial of intramuscular vitamin B12 (hydroxyocobalamin) for the treatment of hyperhomocysteinemia in haemodialysis patients [abstract] Kongres Nasional VIII Annual Meeting Perhimpunan Nefrologi Indonesia; 2002 Oct; Surabaya, Indonesia 2002 2.5"},{"issue":"September, Prog","key":"10.1002\/14651858.CD004683.pub4-BIB0162|cit162","first-page":"55A","article-title":"A randomized placebo controlled trial of intramuscular vitamin B12 (hydroxyocobalamin) for the treatment of hyperhomocysteinemia in haemodialysis patients [abstract no: SU-FC267]","volume":"13","author":"Polkinghorne","year":"2002","journal-title":"Journal of the American Society of Nephrology"},{"issue":"11","key":"10.1002\/14651858.CD004683.pub4-BIB0163|cit163","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1046\/j.1445-5994.2003.00420.x","article-title":"Randomized, placebo-controlled trial of intramuscular vitamin B12 for the treatment of hyperhomocysteinaemia in dialysis patients","volume":"33","author":"Polkinghorne","year":"2003","journal-title":"Internal Medicine Journal"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD004683.pub4-BIB0164|cit164","first-page":"A68","article-title":"A randomised placebo controlled trial of intramuscular vitamin B12 (hydroxyocobalamin) for the treatment of hyperhomocysteinemia in haemodialysis patients [abstract]","volume":"7","author":"Polkinghorne","year":"2002","journal-title":"Nephrology"},{"issue":"6","key":"10.1002\/14651858.CD004683.pub4-BIB0165|cit165","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1053\/j.jrn.2011.01.018","article-title":"Omega-3 fatty acids supplementation does not affect serum lipids in chronic hemodialysis patients","volume":"21","author":"Poulia","year":"2011","journal-title":"Journal of Renal Nutrition"},{"issue":"3","key":"10.1002\/14651858.CD004683.pub4-BIB0166|cit166","first-page":"288","article-title":"Efficacy and safety of two vitamin supplement regimens on homocysteine levels in hemodialysis patients. Prospective, randomized clinical trial","volume":"25","author":"Sanchez Alvarez","year":"2005","journal-title":"Nefrologia"},{"issue":"Nov","key":"10.1002\/14651858.CD004683.pub4-BIB0167|cit167","first-page":"231A","article-title":"Sustained effect of two vitamin supplement regimens on hyperhomocysteinemia in maintenance hemodialysis (MHD) patients [abstract no: F-PO773]","volume":"14","author":"Sanchez","year":"2003","journal-title":"Journal of the American Society of Nephrology"},{"issue":"3","key":"10.1002\/14651858.CD004683.pub4-BIB0168|cit168","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1161\/01.CIR.0000109492.65802.AD","article-title":"Acetylcysteine reduces plasma homocysteine concentration and improves pulse pressure and endothelial function in patients with end-stage renal failure","volume":"109","author":"Scholze","year":"2004","journal-title":"Circulation"},{"key":"10.1002\/14651858.CD004683.pub4-BIB0169|cit169","unstructured":"Scholze A Rinder C Beige J Riezler R Zidek W Tepel M Reduced plasma homocysteine concentration and improved pulse pressure in hemodialysis patients with acetylcysteine [abstract] 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15-18; Lisbon, Portugal 2004 127"},{"issue":"Nov","key":"10.1002\/14651858.CD004683.pub4-BIB0170|cit170","first-page":"497A","article-title":"Effects of folic acid treatment on homocysteine levels and echocardiographic findings in ESRD [abstract no: SA-PO900]","volume":"14","author":"Seo","year":"2003","journal-title":"Journal of the American Society of Nephrology"},{"issue":"9","key":"10.1002\/14651858.CD004683.pub4-BIB0171|cit171","first-page":"A192","article-title":"Hyperhomocysteinemia [HHcy] is not associated with elevated platelet annexin V [plt a-v] expression in maintenance haemodialysis [HD] patients [abstract]","volume":"14","author":"Sepe","year":"1999","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"4 Suppl 1","key":"10.1002\/14651858.CD004683.pub4-BIB0172|cit172","doi-asserted-by":"crossref","first-page":"S91","DOI":"10.1053\/ajkd.2001.27412","article-title":"Treatment of hyperhomocysteinemia in end-stage renal disease","volume":"38","author":"Shemin","year":"2001","journal-title":"American Journal of Kidney Diseases"},{"issue":"3","key":"10.1002\/14651858.CD004683.pub4-BIB0173|cit173","doi-asserted-by":"crossref","first-page":"263","DOI":"10.2165\/00002512-200623030-00008","article-title":"A randomised, controlled clinical trial evaluating changes in therapeutic efficacy and oxidative parameters after treatment with propionyl L-carnitine in patients with peripheral arterial disease requiring haemodialysis","volume":"23","author":"Signorelli","year":"2006","journal-title":"Drugs & Aging"},{"issue":"2","key":"10.1002\/14651858.CD004683.pub4-BIB0174|cit174","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1159\/000094363","article-title":"Propionyl-L-carnitine therapy: effects on endothelin-1 and homocysteine levels in patients with peripheral arterial disease and end-stage renal disease","volume":"29","author":"Signorelli","year":"2006","journal-title":"Kidney & Blood Pressure Research"},{"issue":"2","key":"10.1002\/14651858.CD004683.pub4-BIB0175|cit175","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1002\/cpt1975182200","article-title":"Folic acid dosage for chronic hemodialysis patients","volume":"18","author":"Skoutakis","year":"1975","journal-title":"Clinical Pharmacology & Therapeutics"},{"issue":"Suppl 12","key":"10.1002\/14651858.CD004683.pub4-BIB0176|cit176","first-page":"256","article-title":"Treatment efficacy of folic or folinic acid in lowering total plasma homocysteine levels in patients on hemodialysis [abstract]","volume":"17","author":"Stavrianaki","year":"2002","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"2","key":"10.1002\/14651858.CD004683.pub4-BIB0177|cit177","first-page":"93","article-title":"Effect of different doses of folic acid on serum homocysteine level in patients on hemodialysis","volume":"5","author":"Tamadon","year":"2011","journal-title":"Iranian Journal of Kidney Diseases"},{"issue":"4","key":"10.1002\/14651858.CD004683.pub4-BIB0178|cit178","first-page":"322","article-title":"Effect of omega-3 fatty acid on oxidative stress in patients on hemodialysis","volume":"4","author":"Tayyebi-Khosroshahi","year":"2010","journal-title":"Iranian Journal of Kidney Diseases"},{"issue":"7","key":"10.1002\/14651858.CD004683.pub4-BIB0179|cit179","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1161\/01.CIR.0000050628.11305.30","article-title":"The antioxidant acetylcysteine reduces cardiovascular events in patients with end-stage renal failure: a randomized, controlled trial","volume":"107","author":"Tepel","year":"2003","journal-title":"Circulation"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD004683.pub4-BIB0180|cit180","first-page":"A33","article-title":"Reduction of pulse pressure by intravenous N-acetylcyseine administration in chronic hemodialysis patients [abstract no: 1620]","volume":"11","author":"Thaha","year":"2006","journal-title":"Nephrology"},{"issue":"4","key":"10.1002\/14651858.CD004683.pub4-BIB0182|cit181","doi-asserted-by":"crossref","first-page":"195","DOI":"10.2165\/00044011-200626040-00003","article-title":"Intravenous N-acetylcysteine during haemodialysis reduces the plasma concentration of homocysteine in patients with end-stage renal disease","volume":"26","author":"Thaha","year":"2006","journal-title":"Clinical Drug Investigation"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD004683.pub4-BIB0181|cit182","first-page":"A18","article-title":"Intravenous N-acetylcysteine during haemodialysis reduces the plasma concentration of homocysteine in patients with end-stage renal disease [abstract no: 1560]","volume":"11","author":"Thaha","year":"2006","journal-title":"Nephrology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD004683.pub4-BIB0183|cit183","first-page":"A40","article-title":"Intravenous N-acetylcysteine during hemodialysis reduces homocysteine and asymmetric dimethylarginine in ESRD patients: a randomized double blind controlled trial [abstract no: 1159]","volume":"12","author":"Thaha","year":"2007","journal-title":"Nephrology"},{"issue":"1","key":"10.1002\/14651858.CD004683.pub4-BIB0184|cit184","doi-asserted-by":"crossref","first-page":"24","DOI":"10.5414\/CNP69024","article-title":"Intravenous N-acetylcysteine during hemodialysis reduces asymmetric dimethylarginine level in end-stage renal disease patients","volume":"69","author":"Thaha","year":"2008","journal-title":"Clinical Nephrology"},{"key":"10.1002\/14651858.CD004683.pub4-BIB0185|cit185","first-page":"622A","article-title":"Oral n-acetyl cysteine to treat non-diabetic chronic kidney disease stage 1-4 with albuminuria [abstract no: SA-PO2242]","volume":"20","author":"Thaha","year":"2009","journal-title":"Journal of the American Society of Nephrology"},{"issue":"8","key":"10.1002\/14651858.CD004683.pub4-BIB0186|cit186","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1161\/01.CIR.102.8.871","article-title":"Does folic acid decrease plasma homocysteine and improve endothelial function in patients with predialysis renal failure?","volume":"102","author":"Thambyrajah","year":"2000","journal-title":"Circulation"},{"issue":"Sept","key":"10.1002\/14651858.CD004683.pub4-BIB0187|cit187","first-page":"372A","article-title":"Folic acid decreases plasma homocysteine but does not improve endothelial function in chronic renal failure [abstract]","volume":"11","author":"Thambyrajah","year":"2000","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Sept","key":"10.1002\/14651858.CD004683.pub4-BIB0188|cit188","first-page":"253A","article-title":"Impact on homocysteine levels of folic acid and adherance in haemodialysis patients. A randomized double blind placebo cross over trial [abstract no: A1332]","volume":"11","author":"Tobe","year":"2000","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Program & Abstr","key":"10.1002\/14651858.CD004683.pub4-BIB0189|cit189","first-page":"306A","article-title":"Plasma homocysteine (hcy) levels in patients on chronic haemodialysis are inversely correlated with folate and B12 levels [abstract]","volume":"10","author":"Tobe","year":"1999","journal-title":"Journal of the American Society of Nephrology"},{"issue":"5","key":"10.1002\/14651858.CD004683.pub4-BIB0190|cit190","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1111\/j.1365-2125.2008.03262.x","article-title":"Effects of pre- vs. intra-dialysis folic acid on arterial wave reflections and endothelial function in patients with end-stage renal disease","volume":"66","author":"Tochihara","year":"2008","journal-title":"British Journal of Clinical Pharmacology"},{"issue":"Program & Abstr","key":"10.1002\/14651858.CD004683.pub4-BIB0191|cit191","first-page":"365A","article-title":"High dose folic acid in hemodialysis patients results in frequent side effects without improvement in plasma homocysteine levels [abstract]","volume":"12","author":"Treleaven","year":"2001","journal-title":"Journal of the American Society of Nephrology"},{"issue":"2","key":"10.1002\/14651858.CD004683.pub4-BIB0192|cit192","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1046\/j.1523-1755.2000.00234.x","article-title":"Hyperhomocysteinemia in hemodialysis patients: effects of 12-month supplementation with hydrosoluble vitamins","volume":"58","author":"Tremblay","year":"2000","journal-title":"Kidney International"},{"issue":"1","key":"10.1002\/14651858.CD004683.pub4-BIB0193|cit193","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1159\/000057605","article-title":"Randomized trial of methylcobalamin and folate effects on homocysteine in hemodialysis patients","volume":"91","author":"Trimarchi","year":"2002","journal-title":"Nephron"},{"issue":"Oct","key":"10.1002\/14651858.CD004683.pub4-BIB0194|cit194","first-page":"406A","article-title":"Can folate and vitamin B supplementation reduce total homocysteine levels and atherosclerosis in hemodialysis patients? [abstract no: SA-PO472]","volume":"15","author":"Tungkasereerak","year":"2004","journal-title":"Journal of the American Society of Nephrology"},{"issue":"8","key":"10.1002\/14651858.CD004683.pub4-BIB0195|cit195","first-page":"1187","article-title":"Effect of short-term folate and vitamin B supplementation on blood homocysteine level and carotid artery wall thickness in chronic hemodialysis patients","volume":"89","author":"Tungkasereerak","year":"2006","journal-title":"Journal of the Medical Association of Thailand"},{"issue":"4","key":"10.1002\/14651858.CD004683.pub4-BIB0196|cit196","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.2215\/CJN.04771107","article-title":"Mesna for treatment of hyperhomocysteinemia in hemodialysis patients: a placebo-controlled, double-blind, randomized trial","volume":"3","author":"Urquhart","year":"2008","journal-title":"Clinical Journal of the American Society of Nephrology: CJASN"},{"issue":"9","key":"10.1002\/14651858.CD004683.pub4-BIB0197|cit197","first-page":"A114","article-title":"Treatment of hyperhomocysteinaemia with folic acid does not ameliorate endothelial function in chronic haemodialysis patients [abstract]","volume":"12","author":"Guldener","year":"1997","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Program & Abstr","key":"10.1002\/14651858.CD004683.pub4-BIB0198|cit198","first-page":"274A","article-title":"Folic acid treatment of hyperhomocysteinemia in peritoneal dialysis patients does not ameliorate endothelial function [abstract]","volume":"8","author":"Guldener","year":"1997","journal-title":"Journal of the American Society of Nephrology"},{"issue":"3","key":"10.1002\/14651858.CD004683.pub4-BIB0199|cit199","first-page":"282","article-title":"Folic acid treatment of hyperhomocysteinemia in peritoneal dialysis patients: no change in endothelial function after long-term therapy","volume":"18","author":"Guldener","year":"1998","journal-title":"Peritoneal Dialysis International"},{"issue":"1","key":"10.1002\/14651858.CD004683.pub4-BIB0200|cit200","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1093\/ndt\/13.1.106","article-title":"No change in impaired endothelial function after long-term folic acid therapy of hyperhomocysteinaemia in haemodialysis patients","volume":"13","author":"Guldener","year":"1998","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"9","key":"10.1002\/14651858.CD004683.pub4-BIB0201|cit201","first-page":"1502","article-title":"Treatment of hyperhomocysteinemia in chronic dialysis patients with folic acid and betaine [abstract no: A1266]","volume":"7","author":"Guldener","year":"1996","journal-title":"Journal of the American Society of Nephrology"},{"issue":"5","key":"10.1002\/14651858.CD004683.pub4-BIB0202|cit202","first-page":"A67","article-title":"Folic acid and betaine in the treatment of hyperhomocysteinaemia in haemodialysis patients [abstract]","volume":"48","author":"Guldener","year":"1996","journal-title":"Netherlands Journal of Medicine"},{"issue":"2","key":"10.1002\/14651858.CD004683.pub4-BIB0203|cit203","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1046\/j.1365-2796.1999.00430.x","article-title":"Effect of folic acid and betaine on fasting and postmethionine-loading plasma homocysteine and methionine levels in chronic haemodialysis patients","volume":"245","author":"Guldener","year":"1999","journal-title":"Journal of Internal Medicine"},{"issue":"1","key":"10.1002\/14651858.CD004683.pub4-BIB0204|cit204","first-page":"33","article-title":"Carotid artery stiffness in patients with end-stage renal disease: no effect of long-term homocysteine-lowering therapy","volume":"53","author":"Guldener","year":"2000","journal-title":"Clinical Nephrology"},{"issue":"1","key":"10.1002\/14651858.CD004683.pub4-BIB0205|cit205","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1046\/j.1523-1755.2001.00496.x","article-title":"Long-term reduction of plasma homocysteine levels by super-flux dialyzers in hemodialysis patients","volume":"59","author":"Tellingen","year":"2001","journal-title":"Kidney International"},{"issue":"6","key":"10.1002\/14651858.CD004683.pub4-BIB0206|cit206","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1681\/ASN.V1161106","article-title":"Effect of high dose folic acid therapy on hyperhomocysteinemia in hemodialysis patients: results of the Vienna multicenter study","volume":"11","author":"Sunder-Plassmann","year":"2000","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Program & Abstr","key":"10.1002\/14651858.CD004683.pub4-BIB0207|cit207","first-page":"269A","article-title":"High dose folic acid therapy in hemodialysis (HD) patients. The Vienna multicenter study [abstract]","volume":"10","author":"Sunder-Plassmann","year":"1999","journal-title":"Journal of the American Society of Nephrology"},{"issue":"2","key":"10.1002\/14651858.CD004683.pub4-BIB0208|cit208","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S1567-5688(01)80291-9","article-title":"Effect of vitamin B12 supplementation in serum total homocysteine and folate in patients with end-stage renal failure [abstract]","volume":"2","author":"Vrentzos","year":"2001","journal-title":"Atherosclerosis Supplements"},{"issue":"5","key":"10.1002\/14651858.CD004683.pub4-BIB0209|cit209","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1093\/ajcn\/78.5.1039","article-title":"Acute effect of amino acid peritoneal dialysis solution on vascular function","volume":"78","author":"Vychytil","year":"2003","journal-title":"American Journal of Clinical Nutrition"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD004683.pub4-BIB0210|cit210","first-page":"94","article-title":"Acute effect of amino acid peritoneal dialysis (PD) solution on vascular function - no association with HCY [abstract]","volume":"26","author":"Vychytil","year":"2003","journal-title":"Journal of Inherited Metabolic Disease"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD004683.pub4-BIB0211|cit211","first-page":"215","article-title":"Acute effect of amino acid peritoneal dialysis solution on vascular function [abstract]","volume":"18","author":"Vychytil","year":"2003","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Nov","key":"10.1002\/14651858.CD004683.pub4-BIB0212|cit212","first-page":"741A","article-title":"Acute effect of amino acid peritoneal dialysis solution on vascular function. [abstract no: SU-PO935]","volume":"14","author":"Vychytil","year":"2003","journal-title":"Journal of the American Society of Nephrology"},{"issue":"9275","key":"10.1002\/14651858.CD004683.pub4-BIB0213|cit213","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0140-6736(00)05271-5","article-title":"Effects of fenofibrate and gemfibrozil on plasma homocysteine","volume":"358","author":"Westphal","year":"2001","journal-title":"Lancet"},{"issue":"6","key":"10.1002\/14651858.CD004683.pub4-BIB0214|cit214","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1046\/j.1523-1755.2002.00666.x","article-title":"Distribution of plasma folate forms in hemodialysis patients receiving high daily doses of L-folinic or folic acid","volume":"62","author":"Ghandour","year":"2002","journal-title":"Kidney International"},{"issue":"1","key":"10.1002\/14651858.CD004683.pub4-BIB0215|cit215","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1046\/j.1523-1755.2001.00507.x","article-title":"Rapid communication: L-folinic acid versus folic acid for the treatment of hyperhomocysteinemia in hemodialysis patients","volume":"59","author":"Yango","year":"2001","journal-title":"Kidney International"},{"issue":"6","key":"10.1002\/14651858.CD004683.pub4-BIB0216|cit216","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.jnutbio.2005.08.007","article-title":"N-3 fatty acid supplementation decreases plasma homocysteine in diabetic dyslipidemia treated with statin-fibrate combination","volume":"17","author":"Zeman","year":"2006","journal-title":"Journal of Nutritional Biochemistry"},{"issue":"Program & Abstr","key":"10.1002\/14651858.CD004683.pub4-BIB0217|cit217","first-page":"421A","article-title":"Can high dose of folic acid normalize fast total plama homocysteine (thcy) level in maintenance hemodialysis patients? [abstract]","volume":"12","author":"Zuo","year":"2001","journal-title":"Journal of the American Society of Nephrology"},{"key":"10.1002\/14651858.CD004683.pub4-BIB0218|cit218","unstructured":"Wilcox CS Randomized study of folic acid therapy for hyperhomocysteinemia in patients with end stage renal disease receiving hemodialysis clinicaltrials.gov\/ct2\/show\/NCT00004495"},{"issue":"1","key":"10.1002\/14651858.CD004683.pub4-BIB0219|cit219","first-page":"45","article-title":"Comparison of oral folic acid and folinic acid on blood homocysteine level of patients on hemodialysis","volume":"5","author":"Soleimani","year":"2011","journal-title":"Iranian Journal of Kidney Diseases"},{"issue":"6","key":"10.1002\/14651858.CD004683.pub4-BIB0220|cit220","first-page":"479","article-title":"Effect of omega-3 supplementation on serum level of homocysteine in hemodialysis patients","volume":"7","author":"Tayebi-Khosroshahi","year":"2013","journal-title":"Iranian Journal of Kidney Diseases"},{"issue":"5 Suppl 2","key":"10.1002\/14651858.CD004683.pub4-BIB0221|cit221","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S0272-6386(04)01107-2","article-title":"Dialysis Outcomes and Practice Patterns Study (DOPPS) data on medications in hemodialysis patients","volume":"44","author":"Andreucci","year":"2004","journal-title":"American Journal of Kidney Diseases"},{"issue":"2","key":"10.1002\/14651858.CD004683.pub4-BIB0222|cit222","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1093\/ndt\/gfh620","article-title":"The C677T methylenetetrahydrofolate reductase gene mutation does not influence cardiovascular risk in the dialysis population: results of a multicentre prospective study","volume":"20","author":"Aucella","year":"2005","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"9224","key":"10.1002\/14651858.CD004683.pub4-BIB0223|cit223","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S0140-6736(00)02456-9","article-title":"Premature cardiovascular disease in chronic renal failure","volume":"356","author":"Baigent","year":"2000","journal-title":"Lancet"},{"issue":"4","key":"10.1002\/14651858.CD004683.pub4-BIB0224|cit224","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1681\/ASN.V104891","article-title":"Hyperhomocysteinemia in chronic renal disease","volume":"10","author":"Bostom","year":"1999","journal-title":"Journal of the American Society of Nephrology"},{"key":"10.1002\/14651858.CD004683.pub4-BIB0225|cit225","first-page":"S72","article-title":"Hyperhomocysteinemia, a risk factor for atherosclerosis in chronic uremic patients","volume":"41","author":"Chauveau","year":"1993","journal-title":"Kidney International - Supplement"},{"issue":"16","key":"10.1002\/14651858.CD004683.pub4-BIB0226|cit226","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1001\/jama.2009.1488","article-title":"Cardiovascular and noncardiovascular mortality among patients starting dialysis","volume":"302","author":"Jager","year":"2009","journal-title":"JAMA"},{"issue":"2","key":"10.1002\/14651858.CD004683.pub4-BIB0227|cit227","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1038\/sj.ki.5000096","article-title":"Impact of malnutrition-inflammation on the association between homocysteine and mortality","volume":"69","author":"Ducloux","year":"2006","journal-title":"Kidney International"},{"issue":"7109","key":"10.1002\/14651858.CD004683.pub4-BIB0228|cit228","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"issue":"5","key":"10.1002\/14651858.CD004683.pub4-BIB0229|cit229","doi-asserted-by":"crossref","first-page":"363","DOI":"10.7326\/0003-4819-131-5-199909070-00008","article-title":"Homocyst(e)ine and cardiovascular disease: a critical review of the epidemiologic evidence","volume":"131","author":"Eikelboom","year":"1999","journal-title":"Annals of Internal Medicine"},{"issue":"12 Suppl","key":"10.1002\/14651858.CD004683.pub4-BIB0230|cit230","first-page":"S16","article-title":"Epidemiology of cardiovascular disease in chronic renal disease","volume":"9","author":"Foley","year":"1998","journal-title":"Journal of the American Society of Nephrology"},{"issue":"10","key":"10.1002\/14651858.CD004683.pub4-BIB0231|cit231","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1681\/ASN.V12102181","article-title":"The kidney and homocysteine metabolism","volume":"12","author":"Friedman","year":"2001","journal-title":"Journal of the American Society of Nephrology"},{"issue":"13","key":"10.1002\/14651858.CD004683.pub4-BIB0232|cit232","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1056\/NEJMoa041031","article-title":"Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization.[Erratum appears in N Engl J Med. 2008;18(4):4]","volume":"351","author":"Go","year":"2004","journal-title":"New England Journal of Medicine"},{"issue":"3","key":"10.1002\/14651858.CD004683.pub4-BIB0233|cit233","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1097\/01.mnh.0000165896.98372.f4","article-title":"Folic acid supplementation to prevent adverse events in individuals with chronic kidney disease and end stage renal disease","volume":"14","author":"Gonin","year":"2005","journal-title":"Current Opinion in Nephrology & Hypertension"},{"key":"10.1002\/14651858.CD004683.pub4-BIB0234|cit234","doi-asserted-by":"crossref","first-page":"e3925","DOI":"10.1136\/bmj.e3925","article-title":"Homocysteine, the kidney, and vascular disease","volume":"344","author":"Haynes","year":"2012","journal-title":"BMJ"},{"issue":"7414","key":"10.1002\/14651858.CD004683.pub4-BIB0235|cit235","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD004683.pub4-BIB0236|cit236","unstructured":"Higgins JP Green S (editors) Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"issue":"16","key":"10.1002\/14651858.CD004683.pub4-BIB0237|cit237","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1001\/jama.288.16.2015","article-title":"Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis","volume":"288","author":"Homocysteine Studies Collaboration","year":"2002","journal-title":"JAMA"},{"issue":"4","key":"10.1002\/14651858.CD004683.pub4-BIB0238|cit238","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.clnu.2011.01.003","article-title":"Meta-analysis of B vitamin supplementation on plasma homocysteine, cardiovascular and all-cause mortality","volume":"31","author":"Huang","year":"2012","journal-title":"Clinical Nutrition"},{"key":"10.1002\/14651858.CD004683.pub4-BIB0239|cit239","doi-asserted-by":"crossref","first-page":"e3533","DOI":"10.1136\/bmj.e3533","article-title":"The effect of folic acid based homocysteine lowering on cardiovascular events in people with kidney disease: systematic review and meta-analysis","volume":"344","author":"Jardine","year":"2012","journal-title":"BMJ"},{"issue":"4 Suppl 3","key":"10.1002\/14651858.CD004683.pub4-BIB0240|cit240","first-page":"S1","article-title":"K\/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients","volume":"45","author":"K\/DOQI Workgroup","year":"2005","journal-title":"American Journal of Kidney Diseases"},{"issue":"2","key":"10.1002\/14651858.CD004683.pub4-BIB0241|cit241","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1097\/01.ASN.0000107564.60018.51","article-title":"A low, rather than a high, total plasma homocysteine is an indicator of poor outcome in hemodialysis patients","volume":"15","author":"Kalantar-Zadeh","year":"2004","journal-title":"Journal of the American Society of Nephrology"},{"issue":"3","key":"10.1002\/14651858.CD004683.pub4-BIB0242|cit242","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1093\/ajcn\/81.3.543","article-title":"Survival advantages of obesity in dialysis patients","volume":"81","author":"Kalantar-Zadeh","year":"2005","journal-title":"American Journal of Clinical Nutrition"},{"issue":"3","key":"10.1002\/14651858.CD004683.pub4-BIB0243|cit243","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1007\/s11255-009-9675-1","article-title":"Arterial stiffness in dialysis patients: where are we now?","volume":"42","author":"Kanbay","year":"2010","journal-title":"International Urology & Nephrology"},{"issue":"16","key":"10.1002\/14651858.CD004683.pub4-BIB0244|cit244","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1001\/jama.288.16.2023","article-title":"MTHFR 677C-->T polymorphism and risk of coronary heart disease: a meta-analysis","volume":"288","author":"Klerk","year":"2002","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD004683.pub4-BIB0245|cit245","unstructured":"McDonald S Excell L Livingston B ANZDATA Registry 2007 Report. Chapter 3 Deaths www.anzdata.org.au\/anzdata\/AnzdataReport\/30thReport\/Ch03Deaths.pdf 2007"},{"issue":"12","key":"10.1002\/14651858.CD004683.pub4-BIB0246|cit246","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1161\/CIRCULATIONAHA.105.570127","article-title":"Relationship between homocysteine and mortality in chronic kidney disease","volume":"113","author":"Menon","year":"2006","journal-title":"Circulation"},{"issue":"2","key":"10.1002\/14651858.CD004683.pub4-BIB0247|cit247","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1161\/01.CIR.97.2.138","article-title":"Prospective study of hyperhomocysteinemia as an adverse cardiovascular risk factor in end-stage renal disease.[Erratum appears in Circulation 1998 Feb 24;97(7):711]","volume":"97","author":"Moustapha","year":"1998","journal-title":"Circulation"},{"issue":"3","key":"10.1002\/14651858.CD004683.pub4-BIB0248|cit248","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1017\/S0007114511007033","article-title":"Homocysteine-lowering therapy does not lead to reduction in cardiovascular outcomes in chronic kidney disease patients: a meta-analysis of randomised, controlled trials","volume":"108","author":"Pan","year":"2012","journal-title":"British Journal of Nutrition"},{"issue":"11","key":"10.1002\/14651858.CD004683.pub4-BIB0249|cit249","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1161\/01.CIR.94.11.2743","article-title":"Hyperhomocysteinemia confers an independent increased risk of atherosclerosis in end-stage renal disease and is closely linked to plasma folate and pyridoxine concentrations","volume":"94","author":"Robinson","year":"1996","journal-title":"Circulation"},{"issue":"6","key":"10.1002\/14651858.CD004683.pub4-BIB0250|cit250","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1111\/j.1525-139X.2007.00336.x","article-title":"Homocysteine-lowering is not a primary target for cardiovascular disease prevention in chronic kidney disease patients","volume":"20","author":"Suliman","year":"2007","journal-title":"Seminars in Dialysis"},{"key":"10.1002\/14651858.CD004683.pub4-BIB0251|cit251","unstructured":"U.S. Renal Data System, USRDS 2007 Annual Data Report: Atlas of End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2007 www.usrds.org\/atlas07.aspx (accessed January 2016)"},{"issue":"5","key":"10.1002\/14651858.CD004683.pub4-BIB0252|cit252","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1093\/ndt\/gfl044","article-title":"Why is homocysteine elevated in renal failure and what can be expected from homocysteine-lowering?","volume":"21","author":"Guldener","year":"2006","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"9","key":"10.1002\/14651858.CD004683.pub4-BIB0253|cit253","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/S1474-4422(10)70187-3","article-title":"B vitamins in patients with recent transient ischaemic attack or stroke in the VITAmins TO Prevent Stroke (VITATOPS) trial: a randomised, double-blind, parallel, placebo-controlled trial","volume":"9","author":"VITATOPS Trial Study Group","year":"2010","journal-title":"Lancet Neurology"},{"issue":"7374","key":"10.1002\/14651858.CD004683.pub4-BIB0254|cit254","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1136\/bmj.325.7374.1202","article-title":"Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis","volume":"325","author":"Wald","year":"2002","journal-title":"BMJ"},{"issue":"5","key":"10.1002\/14651858.CD004683.pub4-BIB0255|cit255","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1097\/01.ASN.0000123691.46138.E2","article-title":"Chronic kidney disease as a risk factor for cardiovascular disease and all-cause mortality: a pooled analysis of community-based studies","volume":"15","author":"Weiner","year":"2004","journal-title":"Journal of the American Society of Nephrology"},{"issue":"3","key":"10.1002\/14651858.CD004683.pub4-BIB0256|cit256","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1046\/j.1523-1755.2001.0600031106.x","article-title":"An MTHFR variant, homocysteine, and cardiovascular comorbidity in renal disease","volume":"60","author":"Wrone","year":"2001","journal-title":"Kidney International"},{"issue":"3","key":"10.1002\/14651858.CD004683.pub4-BIB0257|cit257","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.bone.2012.05.024","article-title":"Homocysteine level and risk of fracture: A meta-analysis and systematic review","volume":"51","author":"Yang","year":"2012","journal-title":"Bone"},{"issue":"12","key":"10.1002\/14651858.CD004683.pub4-BIB0258|cit258","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1038\/nrneph.2010.142","article-title":"Hyperhomocysteinemia: a renal and cardiovascular risk factor?","volume":"6","author":"Zoccali","year":"2010","journal-title":"Nature Reviews Nephrology"},{"issue":"2","key":"10.1002\/14651858.CD004683.pub4-BIB0259|cit259","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004683.pub3","article-title":"Interventions for lowering plasma homocysteine levels in dialysis patients","author":"Nigwekar","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD004683.pub4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,17]],"date-time":"2024-06-17T07:16:57Z","timestamp":1718608617000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD004683.pub4"}},"subtitle":[],"editor":[{"name":"Cochrane Kidney and Transplant Group","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2016,5,31]]},"references-count":259,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2016,5]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd004683.pub4","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,5,31]]}}}